SCHEMBL247109

SCHEMBL247109

COc1ccc(-c2cnc(Cl)cc2N)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
PTGS2 P35354 6/20 0.45
PTGS1 P23219 5/20 0.45
KIT P10721 1/20 0.45
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
FYN P06241 1/20 0.43
KCNQ3 O43525 1/20 0.43
KCNQ2 O43526 1/20 0.43
CD274 Q9NZQ7 1/20 0.41
EPHB4 P54760 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL246142 0.86 ALOX5AP (0.48) ALOX5APFEN1KCNQ3KCNQ2
SCHEMBL30630871 0.84 PDGFRB (0.49) ALDH1A1MEN1NPC1RAB9AKMT2A
SCHEMBL27440493 0.84 PDGFRB (0.49) ALDH1A1MEN1NPC1RAB9AKMT2A
SCHEMBL27440496 0.81 PDGFRB (0.46) ALDH1A1MEN1NPC1RAB9AKMT2A
SCHEMBL1388354 0.76 DHFR (0.68) ALDH1A1MEN1NPC1RAB9AKMT2A
SCHEMBL247317 0.75 KCNH2 (0.47) PDGFRBPDGFRAFYN
SCHEMBL3996401 0.75 CYP17A1 (0.52) ALDH1A1MEN1NPC1RAB9AKMT2A
SCHEMBL246958 0.74 ALK (0.49) MEN1KMT2AKITFYN
SCHEMBL27855773 0.74 ADORA2A (0.56) ALDH1A1MEN1NPC1RAB9AKMT2A
SCHEMBL247986 0.74 DYRK1A (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 ALDH1A1 3735/4885MEN1 1146/4885NPC1 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.